论文部分内容阅读
目的:探讨63例人类肺癌中p53、Bcl-2的表达。方法:采用免疫组织化学方法,以抗p53多抗标记p53蛋白,抗Bcl—2单抗标记Bcl-2蛋白。结果:所有肺癌组织中,p53突变率54％(34/63),Bcl-2蛋白表达率44.4％(28/63)。p53突变率与组织类型、临床分期、病人性别、年龄等临床参数无关;Bcl—2表达在Ⅰ、Ⅱ期(55.3％)明显高于Ⅲ、Ⅳ期(28％)(P<0.05),而与组织类型无关;Bcl—2蛋白表达与p53蛋白表达不相关。结论:人类肺癌的发生发展与p53、Bcl-2蛋白过度表达有关;Bcl-2蛋白表达可能为肺癌早期事件,可作为评定预后的生物学指标;p53蛋白表达与组织类型、临床分期等参数无关。
Objective: To investigate the expression of p53 and Bcl-2 in 63 human lung carcinomas. Methods: Immunohistochemical method was used to detect the p53 protein with anti-p53 polyclonal antibody and Bcl-2 protein with anti-Bcl-2 monoclonal antibody. Results: The p53 mutation rate was 54% (34/63) and the Bcl-2 protein expression rate was 44.4% (28/63) in all lung cancer tissues. The mutation rate of p53 was not related to clinical parameters such as histological type, clinical stage, patient’s gender and age. The expression of Bcl-2 was significantly higher in stageⅠand Ⅱ (55.3%) than in stage Ⅲ and Ⅳ (28%) (P <0.05) Regardless of the type of tissue; Bcl-2 protein expression and p53 protein expression is not related. Conclusions: The occurrence and development of human lung cancer is related to the overexpression of p53 and Bcl-2 protein. The expression of Bcl-2 protein may be an early stage of lung cancer and may be used as a biological indicator to evaluate the prognosis. The expression of p53 protein is not related to the type of tissue, clinical stage and other parameters .